欧洲难治性癫痫治疗市场：分析与预测（2025-2035）

欧洲难治性癫痫治疗市场规模预计将从 2024 年的 13.432 亿美元增至 2035 年的 28.228 亿美元，预测期内的复合年增长率为 6.98%。

欧洲治疗难治性癫痫的模式正在转向更加个人化，充分利用每位患者的临床特征、基因标记和生活方式选择。欧洲医疗机构正在突破传统的「一刀切」模式，结合基因组学、分子诊断和高阶数据分析领域的发展，制定个人化治疗方案。除了改善癫痫发作控制和减少副作用外，这项精准技术还能最大限度地减少昂贵的试验药物。

欧洲药品管理局 (EEA) 的严格监管、跨境临床註册以及强大的欧洲生物样本库基础设施，正在加速新型抗癫痫药物的检验和生物标记的开发。预测演算法能够及早发现抗药性患者，从而能够及时采用神经调节疗法和标靶药物进行干预。学术机构、癫痫专科诊所以及生命科学产业创新者之间的合作，也推动着涵盖西欧、中欧和东欧的精准神经病学网络 (Precision Neurology Network) 实现更精准的预后、更早期的诊断和更优化的治疗途径。这有望改善患者的治疗效果，并实现更具成本效益的医疗服务。

欧洲难治性癫痫治疗市场正在迅速变化，医疗保健专业人员和医疗体係正转向更个人化、技术主导的治疗方案，以应对那些无法透过第一线药物控制癫痫发作的患者。该市场涵盖先进药物、神经调节设备和新兴生物製药，其特点是，在欧洲约600万癫痫患者中，约30%的患者存在抗药性。随着人们日益意识到难治性癫痫带来的重大临床和经济负担，推动了对创新治疗方法和诊断工具的投资，从而实现早期发现和介入。

下一代抗癫痫药物（基于大麻二酚的辅助性治疗和新型分子实体）和神经调节技术（例如深部脑部刺激 (DBS)、迷走神经刺激 (VNS) 和反应性神经刺激 (RNS)）为癫痫发作控制提供了新的途径，已成为重要的细分市场。欧盟医疗设备法规 (MDR) 和欧洲药品管理局 (EMA) 的严格监督确保了这些药物的高安全性和有效性，而西欧健全的报销制度以及中东欧国家不断增长的医疗支出也推动了这些药物的推广应用。

此外，分子诊断、基于人工智慧的预测演算法和基因组分析等技术进步正在为精准医疗铺路，减少试验用药，改善治疗效果。然而，挑战依然存在：缺乏专业的癫痫中心、高昂的治疗费用以及医疗服务可近性的地区差异阻碍了市场扩张。儘管如此，临床专家、生物製药公司和学术研究网络之间的合作正在为更有针对性和更有效的干预措施奠定基础，难治性癫痫的治疗正迅速成为欧洲神经系统疾病的重点领域之一。

市场区隔:

细分一：按地区

• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

本报告调查了欧洲难治性癫痫治疗市场，并总结了主要趋势、市场影响因素分析、通路趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章市场：产业展望

• 主要趋势
• 难治性癫痫治疗市场趋势
  • 治疗难治性癫痫的新型标靶治疗
  • 商务策略
  • 企业策略
  • 市场机会
• Start-Ups概况
  • 生态系中的关键Start-Ups
• 研发药物：难治性癫痫的治疗
• 趋势
  • 治疗难治性癫痫的新型标靶治疗
• 市场动态
  • 趋势、驱动因素、挑战和机会：评估当前和未来的影响
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场挑战

第二章 区域

• 区域摘要
• 欧洲
  • 区域概况
  • 市场成长动力
  • 市场问题
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 英国
  • 其他的

第三章市场：竞争基准化分析与公司概况

• Biocodex-SP
• GSK plc.
• LivaNova PLC
• Novartis AG
• UCB SA

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Europe Refractory Epilepsy Treatment Market

The Europe refractory epilepsy treatment market is projected to reach $2,822.8 million by 2035 from $1,343.2 million in 2024, growing at a CAGR of 6.98% during the forecast period 2025-2035. The paradigm for treating refractory epilepsy in Europe is changing to one that is more individualised and makes use of each patient's clinical profile, genetic markers, and lifestyle choices. Beyond the conventional ""one-size-fits-all"" approach, European healthcare providers can create customised treatment plans by combining developments in genomics, molecular diagnostics, and advanced data analytics. In addition to improving seizure control and lowering side effects, this precise technique also minimises expensive trial-and-error dosing.

The European Medicines Agency's strict regulations, cross-border clinical registries, and Europe's strong biobanking infrastructure are helping to validate new antiseizure drugs and speed up the development of biomarkers. Timely intervention with neuromodulation or targeted pharmaceuticals is made possible by the early detection of drug-resistant patients using prediction algorithms. Collaboration between academic institutions, speciality epilepsy clinics, and life-science innovators promises more precise prognoses, earlier diagnoses, and optimised treatment pathways as precision neurology networks spread throughout Western, Central, and Eastern Europe. This will ultimately improve patient outcomes and drive cost-effective care.

Market Introduction

The market for refractory epilepsy treatments in Europe is rapidly changing as medical professionals and healthcare systems shift towards more individualised, technologically driven care for individuals whose seizures are still uncontrollable with first-line treatments. The market, which includes advanced pharmaceuticals, neuromodulation devices, and emerging biologics, is characterised by drug-resistant cases, which affect approximately 30% of the estimated 6 million individuals with epilepsy on the continent. Investment in innovative treatments and diagnostic tools that facilitate earlier detection and intervention is being driven by growing awareness of the significant clinical and financial burden of refractory epilepsy.

Next-generation antiseizure drugs (like cannabidiol-based adjuncts and novel molecular entities) and neuromodulation technologies (like deep brain stimulation (DBS), vagus nerve stimulation (VNS), and responsive neurostimulation (RNS)) that provide alternate methods of controlling seizures are important market segments. While strict EU Medical Device Regulation (MDR) and EMA oversight guarantee high levels of safety and efficacy, adoption is being aided by Western Europe's favourable reimbursement environment and Central and Eastern Europe's growing healthcare spending.

Molecular diagnostics, AI-powered predictive algorithms, and genomic profiling are some of the technological advancements that are enabling precision treatment paths, decreasing trial-and-error prescribing, and increasing patient outcomes. However, obstacles still exist: a lack of specialised epilepsy centres, high therapeutic costs, and unequal access across regions impede expansion. However, cooperation between clinical experts, biopharma firms, and academic research networks is creating the foundation for more focused, successful interventions and making the treatment of refractory epilepsy a crucial area of attention within the larger neurology industry in Europe.

Market Segmentation:

Segmentation 1: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Refractory Epilepsy Treatment Market Trends, Drivers and Challenges

Trends

• Rising uptake of neuromodulation therapies (Vagus Nerve Stimulation, Responsive Neurostimulation, Deep Brain Stimulation) alongside pharmacologic options
• Growth in cannabidiol (CBD)-based and other novel adjunctive medications following EU approvals
• Expansion of precision medicine approaches, including genetic profiling to tailor treatment regimens
• Increased use of tele-health and remote monitoring platforms for treatment adherence and seizure tracking

Drivers

• Persistent unmet need: ~30% of epilepsy patients remain drug-resistant despite multiple AED trials
• Strong R&D pipeline and strategic partnerships between pharma and device manufacturers
• Supportive reimbursement frameworks and increasing healthcare budgets in many European countries
• Patient advocacy and greater disease awareness driving early specialist referrals

Challenges

• High cost of advanced therapies and unequal access across Western versus Eastern Europe
• Complex regulatory environment for novel biologics and devices under EU MDR
• Limited number of specialized epilepsy centers and trained multidisciplinary teams
• Variability in national treatment guidelines and slow adoption of cutting-edge options in some markets

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in refractory epilepsy treatment, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Refractory Epilepsy Treatment solutions.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• UCB S.A.
• Novartis AG
• LivaNova PLC
• GSK plc.
• Biocodex-SP

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Major Trend
• 1.2 Trend in Refractory Epilepsy Treatment Market
  • 1.2.1 Emerging Targeted Therapy for Refractory Epilepsy Treatment
  • 1.2.2 Business Strategies
    • 1.2.2.1 Product Developments
    • 1.2.2.2 Market Developments
  • 1.2.3 Corporate Strategies
    • 1.2.3.1 Partnerships and Joint Ventures
  • 1.2.4 Market Opportunities
    • 1.2.4.1 Advances in Neuromodulation Devices in the Refractory Epilepsy Treatment Market
    • 1.2.4.2 Shift from Neo-Adjuvant Approaches Driven by Diagnostic Advancements
• 1.3 Start-Ups Landscape
  • 1.3.1 Key Start-Ups in the Ecosystem
• 1.4 Pipeline Drugs, Refractory Epilepsy Treatment
• 1.5 Trends
  • 1.5.1 Emerging Targeted Therapy for Refractory Epilepsy Treatment
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • 1.6.2 Market Drivers
    • 1.6.2.1 Increasing Prevalence of Drug-resistant Epilepsy and Ever-expanding Pipeline of Novel Therapeutics
    • 1.6.2.2 Growing Impact of Orphan Drug Development and Role of Advocacy Groups and Awareness Programs
    • 1.6.2.3 Emerging Treatment Modalities in Refractory Epilepsy
  • 1.6.3 Market Restraints
    • 1.6.3.1 Off-Label Medication Practices Hindering the Refractory Epilepsy Treatment Market
    • 1.6.3.2 High R&D Cost as a Barrier to New Entry for New and Small-Scale Companies
  • 1.6.4 Market Opportunities
    • 1.6.4.1 Advances in Neuromodulation Devices in the Refractory Epilepsy Treatment Market
    • 1.6.4.2 Shift from Neo-Adjuvant Approaches Driven by Diagnostic Advancements
  • 1.6.5 Market Challenges
    • 1.6.5.1 Financial Constraints on Patient Access
    • 1.6.5.2 Underdiagnosis of Patients who Meet the Criteria for Drug-Resistant Epilepsy (DRE)

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Germany
  • 2.2.5 France
  • 2.2.6 Italy
  • 2.2.7 Spain
  • 2.2.8 U.K.
  • 2.2.9 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Biocodex-SP
  • 3.1.1 Overview
  • 3.1.2 Top Products/Product Portfolio
  • 3.1.3 Top Competitors
  • 3.1.4 Target Customers
  • 3.1.5 Strategic Positioning and Market Impact
  • 3.1.6 Analyst View
  • 3.1.7 Pipeline and Research Initiatives
• 3.2 GSK plc.
  • 3.2.1 Overview
  • 3.2.2 Top Products/Product Portfolio
  • 3.2.3 Top Competitors
  • 3.2.4 Target Customers
  • 3.2.5 Strategic Positioning and Market Impact
  • 3.2.6 Analyst View
  • 3.2.7 Research Initiatives
• 3.3 LivaNova PLC
  • 3.3.1 Overview
  • 3.3.2 Top Products/Product Portfolio
  • 3.3.3 Top Competitors
  • 3.3.4 Target Customers
  • 3.3.5 Strategic Positioning and Market Impact
  • 3.3.6 Analyst View
  • 3.3.7 Research Initiatives
• 3.4 Novartis AG
  • 3.4.1 Overview
  • 3.4.2 Top Products/Product Portfolio
  • 3.4.3 Top Competitors
  • 3.4.4 Target Customers
  • 3.4.5 Strategic Positioning and Market Impact
  • 3.4.6 Analyst View
  • 3.4.7 Pipeline and Research Initiatives
• 3.5 UCB S.A.
  • 3.5.1 Overview
  • 3.5.2 Top Products/Product Portfolio
  • 3.5.3 Top Competitors
  • 3.5.4 Target Customers
  • 3.5.5 Strategic Positioning and Market Impact
  • 3.5.6 Analyst View
  • 3.5.7 Pipeline and Research Initiative

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Refractory Epilepsy Treatment Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Europe Refractory Epilepsy Treatment Market, 2024-2035
• Figure 3: Timeline of Drugs Launched for Refractory Epilepsy Treatment
• Figure 4: Europe Refractory Epilepsy Treatment Market Snapshot
• Figure 5: Refractory Epilepsy Treatment Market, $Million, 2024 and 2035
• Figure 6: Europe Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 7: Germany Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 8: France Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 9: Italy Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 10: Spain Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 11: U.K. Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 12: Rest-of-Europe Refractory Epilepsy Treatment Market, $Million, 2023-2035
• Figure 13: Inclusion and Exclusion
• Figure 14: Data Triangulation
• Figure 15: Top-Down and Bottom-Up Approach
• Figure 16: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Recent Investments in Refractory Epilepsy Treatment
• Table 3: Key Development in Seizure Management by Key Companies
• Table 4: Start-ups and Investment Landscape
• Table 5: Pipeline Drugs and its Clinical Trial Phase
• Table 6: Recent Investments in Refractory Epilepsy Treatment
• Table 7: Major Development in the Refractory Epilepsy Treatment Market
• Table 8: Major Development in Refractory Epilepsy Treatment Market
• Table 9: Major Drugs and Their Indication
• Table 10: Major Devices Used in the Refractory Epilepsy Treatment Market
• Table 11: Refractory Epilepsy Treatment Market (by Regio), $Million, 2023-2035
• Table 12: Europe Refractory Epilepsy Treatment Market (By Country), $Million, 2023-2035